Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation (Oncogene, (2016), 35, 22, (2862-2872), 10.1038/onc.2015.355);NFATc2 is an intrinsic regulator of melanoma dedifferentiation

Oncogene

Volumn 35, Issue 22, 2016, Pages 2862-2872

  Perotti, V ^a   Baldassari, P ^a   Molla, A ^a   Vegetti, C ^a   Bersani, I ^a   Maurichi, A ^a   Santinami, M ^a   Anichini, A ^a   Mortarini, R ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRN2 PROTEIN; CD271 ANTIGEN; GLYCOPROTEIN GP 100; MELAN A; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; MYC PROTEIN; PGC1 ALPHA PROTEIN; PROTEIN; RAB27A PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; ADAPALENE; HOMEODOMAIN PROTEIN; MELANOMA ANTIGEN; TRANSCRIPTION FACTOR BRN-2; TRANSCRIPTION FACTOR POU;

ANTIGEN EXPRESSION; ARTICLE; CELL DEDIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; SKIN PIGMENTATION; UPREGULATION; CYTOTOXIC T LYMPHOCYTE; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR ESCAPE;

ADAPALENE; CELL DEDIFFERENTIATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HOMEODOMAIN PROTEINS; HUMANS; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NFATC TRANSCRIPTION FACTORS; POU DOMAIN FACTORS; PROTO-ONCOGENE PROTEINS C-MYC; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 84973402630     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-019-0679-8     Document Type: Erratum

References (51)

1. Kemper K, de Goeje PL, Peeper DS, van Amerongen R. Phenotype switching: Tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Res 2014; 74: 5937-5941.
2. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490: 412-416.
3. Ravindran Menon DS, Das S, Krepler C, Vultur A, Rinner B, Schauer S et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene 2014; 34: 4448-4459.
4. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 2013; 24: 466-480.
5. Cheli Y, Bonnazi VF, Jacquel A, Allegra M, De Donatis GM, Bahadoran et al. CD271 is an imperfect marker for melanoma initiating cells. Oncotarget 2014; 5: 5272-5283.
6. Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A et al. A melanoma cell state distinction influences sensitivity to MAPK inhibitors. Cancer Discov 2014; 4: 816-827.
7. Möller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun 2014; 5: 5712.
8. Furuta J, Inozume T, Harada K, Shimada S. CD271 on melanoma cell is an IFN-gamma-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Invest Dermatol 2014; 134: 1369-1377.
9. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012; 31: 4898-4911.
10. Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K et al. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ 2014; 21: 1250-1261.
11. Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci 2015; 72: 1249-1260.
12. Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fifteen-year quest for microphthalmiaassociated transcription factor target genes. Pigment Cell Melanoma Res 2010; 23: 27-40.
13. Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008; 68: 650-656.
14. Medyouf H, Ghysdael J. The calcineurin/NFAT signaling pathway: A novel therapeutic target in leukemia and solid tumors. Cell Cycle 2008; 7: 297-303.
15. Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 2009; 9: 810-820.
16. Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E et al. NFATc2 is a potential therapeutic target in human melanoma. J Invest Dermatol 2012; 132: 2652-2660.
17. Flockhart RJ, Armstrong JL, Reynolds NJ, Lovat PE. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Br J Cancer 2009; 101: 1448-1455.
18. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133-137.
19. Caballero FJ, Navarrete CM, Hess S, Fiebich BL, Appendino G, Macho A et al. The acetaminophen-derived bioactive N-Acylphenolamine AM404 inhibits NFAT by targeting nuclear regulatory events. Biochem Pharmacol 2007; 73: 1013-1023.
20. Kaminuma O, Kitamura F, Kitamura N, Hiroi T, Miyoshi H, Miyawaki A et al. Differential contribution of NFATc2 and NFATc1 to TNF-Alpha gene expression in T cells. J Immunol 2008; 180: 319-326.
21. Mognol GP, de Araujo-Souza PS, Robbs BK, Teixeira LK, Viola JP. Transcriptional regulation of the c-Myc promoter by NFAT1 involves negative and positive NFAT-responsive elements. Cell Cycle 2012; 11: 1014-1028.
22. Singh G, Singh SK, Konig A, Reutlinger K, Nye MD, Adhikary T et al. Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 2010; 285: 27241-27250.
23. Ninomiya-Tsuji J, Torti FM, Ringold GM. Tumor necrosis factor-induced c-myc expression in the absence of mitogenesis is associated with inhibition of adipocyte differentiation. Proc Natl Acad Sci USA 1993; 90: 9611-9615.
24. Takada Y, Ichikawa H, Pataer A, Swisher S, Aggarwal BB. Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. Oncogene 2007; 26: 1201-1212.
25. Goodall J, Carreira S, Denat L, Kobi D, Davidson I, Nuciforo P et al. Brn-2 represses microphthalmia-Associated transcription factor expression and marks a distinct subpopulation of microphthalmia-Associated transcription factor-negative melanoma cells. Cancer Res 2008; 68: 7788-7794.
26. Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-Antigens in human metastatic melanoma. Cancer Res 2003; 63: 2535-2545.
27. Romero P, Cerottini JC, Speiser DE. The human T cell response to melanoma antigens. Adv Immunol 2006; 92: 187-224.
28. Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun 2015; 6: 6683.
29. Mammucari C, Tommasi di Vignano A, Sharov AA, Neilson J, Havrda MC, Roop DR et al. Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control. Dev Cell 2005; 8: 665-676.
30. Santini MP, Talora C, Seki T, Bolgan L, Dotto GP. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA 2001; 98: 9575-9580.
31. Zhou Y, Wang Q, Weiss HL, Evers BM. Nuclear factor of activated T-cells 5 increases intestinal goblet cell differentiation through an mTOR/Notch signaling pathway. Mol Biol Cell 2014; 25: 2882-2890.
32. Phuong TT, Yun YH, Kim SJ, Kang TM. Positive feedback control between STIM1 and NFATc3 is required for C2C12 myoblast differentiation. Biochem Biophys Res Commun 2013; 430: 722-728.
33. Barral AM, Kallstrom R, Sander B, Rosen A. Thioredoxin, thioredoxin reductase and tumour necrosis factor-Alpha expression in melanoma cells: correlation to resistance against cytotoxic attack. Melanoma Res 2000; 10: 331-343.
34. Oliver JL, Alexander MP, Norrod AG, Mullins IM, Mullins DW. Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas. Pigment Cell Melanoma Res 2013; 26: 571-579.
35. Lopez-Rodriguez C, Aramburu J, Jin L, Rakeman AS, Michino M, Rao A. Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress. Immunity 2001; 15: 47-58.
36. Minematsu H, Shin MJ, Celil Aydemir AB, Kim KO, Nizami SA, Chung GJ et al. Nuclear presence of nuclear factor of activated T cells (NFAT) c3 and c4 is required for Toll-like receptor-Activated innate inflammatory response of monocytes/macrophages. Cell Signal 2011; 23: 1785-1793.
37. Lawrence MC, Naziruddin B, Levy MF, Jackson A, McGlynn K. Calcineurin/nuclear factor of activated T cells and MAPK signaling induce TNF-{alpha} gene expression in pancreatic islet endocrine cells. J Biol Chem 2011; 286: 1025-1036.
38. Pouryazdanparast P, Brenner A, Haghighat Z, Guitart J, Rademaker A, Gerami P. The role of 8q24 copy number gains and c-MYC expression in amelanotic cutaneous melanoma. Mod Pathol 2012; 25: 1221-1226.
39. Shou J, Jing J, Xie J, You L, Jing Z, Yao J et al. Nuclear factor of activated T cells in cancer development and treatment. Cancer Lett 2015; 361: 174-184.
40. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 1999; 18: 2967-2987.
41. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 2008; 3: e2734.
42. Harris RG, White E, Phillips ES, Lillycrop KA. The expression of the developmentally regulated proto-oncogene Pax-3 is modulated by N-Myc. J Biol Chem 2002; 277: 34815-34825.
43. Bonvin E, Falletta P, Shaw H, Delmas V, Goding CR. A phosphatidylinositol 3-kinase-Pax-3 axis regulates Brn-2 expression in melanoma. Mol Cell Biol 2012; 32: 4674-4683.
44. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004; 23: 5968-5977.
45. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E et al. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 2006; 66: 6405-6411.
46. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 2006; 25: 3357-3364.
47. Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V et al. Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res 2012; 18: 3316-3327.
48. Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E et al. Synergistic anti-Tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. Cell Death Dis 2014; 5: e1434.
49. Yuan JS, Reed A, Chen F, Stewart CN Jr. Statistical analysis of real-Time PCR data. BMC Bioinformatics 2006; 7: 85.
50. Bellei B, Pitisci A, Catricala C, Larue L, Picardo M. Wnt/beta-catenin signaling is stimulated by alpha-melanocyte-stimulating hormone in melanoma and melanocyte cells: implication in cell differentiation. Pigment Cell Melanoma Res 2011; 24: 309-325.
51. Mortarini R, Scarito A, Nonaka D, Zanon M, Bersani I, Montaldi et al. Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles. Cancer Res 2005; 65: 3428-3436.